DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $59.91, for a total value of $101,847.00.
• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $63.04, for a total value of $107,168.00.

DexCom Trading Down 2.6%

DXCM opened at $71.23 on Thursday. The firm has a market capitalization of $27.49 billion, a P/E ratio of 30.44, a P/E/G ratio of 1.14 and a beta of 1.45. The firm’s 50 day moving average is $66.75 and its 200-day moving average is $67.82. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 earnings per share. Analysts expect that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Empowered Funds LLC increased its stake in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the last quarter. Focus Partners Wealth increased its stake in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Robert W. Baird set a $80.00 target price on DexCom in a research report on Friday, May 1st. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a report on Tuesday, March 24th. Mizuho set a $85.00 price objective on DexCom and gave the stock an “outperform” rating in a report on Tuesday, June 9th. Finally, Benchmark began coverage on shares of DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.